The SEC and the Justice Department studied Merck's handling of Vioxx. Merck was unsure whether their insurance would be adequate against lawsuits. Moody's dropped Merck's credit rating because of litigation exposure. A clinical trial of Celebrex, a drug similar to Vioxx, was shut down when researchers found increased risk of heart disease and stroke A Senate Committee heard testimony that Merck and the FDA were aware of the Vioxx risks before the drug was approved. Merck adopted a plan to protect 230 of their top executives in case financial trouble necessitated a takeover. 